Literature DB >> 27617663

Sorafenib plus cisplatin for hepatocellular carcinoma.

Vicki Brower.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27617663     DOI: 10.1016/S1470-2045(16)30447-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Underlying mechanism of sorafenib resistance in hepatocellular carcinoma: a bioinformatics study based on validated resistance-related genes.

Authors:  Yu Song; Peng Gao; Haiying Ding; Gaoqi Xu; Yan Hu; Yinghui Tong; Wenxiu Xin; Liwen Zhang; Miaolian Wu; Luo Fang
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Xue-Qin Zhang; Peng Lin; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.

Authors:  Song Zou; Chen Wang; Jiansheng Liu; Qun Wang; Dongdong Zhang; Shengnan Zhu; Shengyuan Xu; Mafei Kang; Shaozhong He
Journal:  Mol Cells       Date:  2017-11-10       Impact factor: 5.034

4.  Cisplatin chemotherapy-induced miRNA-210 signaling inhibits hepatocellular carcinoma cell growth.

Authors:  Huan Yu; Guangyue Shi
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.